

DAFTAR PUSTAKA

Aggarwal, Alisha *et al.* (2020) 'Iron-deficiency anemia among adolescents: A global public health concern', *International Journal of Advanced Community Medicine*, 3, pp. 35–40. doi:[10.33545/comed.2020.v3.i2a.148](https://doi.org/10.33545/comed.2020.v3.i2a.148).

Akira, S., Taga, T. and Kishimoto, T. (1993) 'Interleukin-6 in Biology and Medicine', in Dixon, F.J. (ed.) *Advances in Immunology*. Academic Press, pp. 1–78. doi:[10.1016/S0065-2776\(08\)60532-5](https://doi.org/10.1016/S0065-2776(08)60532-5).

Burger, R. (2013) 'Impact of interleukin-6 in hematological malignancies', *Transfusion Medicine and Hemotherapy: Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie*, 40(5), pp. 336–343. doi:[10.1159/000354194](https://doi.org/10.1159/000354194).

Cortes, J. and Kurzrock, R. (1997) 'Interleukin-10 in non-Hodgkin's lymphoma', *Leukemia & Lymphoma*, 26(3–4), pp. 251–259. doi:[10.3109/10428199709051774](https://doi.org/10.3109/10428199709051774).

Globocan 2020. (2021). The Global Cancer Observatory, 1-2

Grimm, K.E. and O'Malley, D.P. (2019) 'Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues', *Annals of Diagnostic Pathology*, 38, pp. 6–10. doi:[10.1016/j.anndiagpath.2018.09.014](https://doi.org/10.1016/j.anndiagpath.2018.09.014).

Guney, N. *et al.* (2009) 'Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin's lymphoma', *Asian Pacific journal of cancer prevention: APJCP*, 10(4), pp. 669–674.

Hong, J. *et al.* (2014) 'Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy', *Cancer Science*, 105(12), pp. 1569–1575. doi:[10.1111/cas.12544](https://doi.org/10.1111/cas.12544).

Huang, P. *et al.* (2017) 'Effects of IL-10 on iron metabolism in LPS-induced inflammatory mice via modulating hepcidin expression', *European Review for Medical and Pharmacological Sciences*, 21(15), pp. 3469–3475.

Jaffe, E.S., Harris, N.L., Stein, H., Vardiman, J.W., editors. *Parhology and genetics of tumours of haematopoietic and lymphoid tissue*. Lyon, France: IARC Press; 2001

Julianty, P. F. ., Ham, M. F., Kusmardi, K., & Harahap, A. S. (2020). CD30 Expression in Germinal Center B- cell-like and non-Germinal Center Bcell-like Subtypes of Diffuse Large B-cell Lymphoma. *Open Access Macedonian Journal of Medical Sciences*, 8(B), 375–380. <https://doi.org/10.3889/oamjms.2020.4645>

Küppers, R., Engert, A. and Hansmann, M.-L. (2012) 'Hodgkin lymphoma', *The Journal of Clinical Investigation*, 122(10), pp. 3439–3447. doi:[10.1172/JCI61245](https://doi.org/10.1172/JCI61245).

Lech-Maranda, E. *et al.* (2004) 'Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma', *Blood*, 103(9), pp. 3529–3534. doi:[10.1182/blood-2003-06-1850](https://doi.org/10.1182/blood-2003-06-1850).

Li, S., Young, K.H. and Medeiros, L.J. (2018) 'Diffuse large B-cell lymphoma', *Pathology*, 50(1), pp. 74–87. doi:[10.1016/j.pathol.2017.09.006](https://doi.org/10.1016/j.pathol.2017.09.006).



Lichtenstein, A. (2014) 'Anemia in lymphoma: interleukin-6, hepcidin and erythropoietin', *Leukemia & Lymphoma*, 55(2), pp. 231–232. doi:[10.3109/10428194.2013.804521](https://doi.org/10.3109/10428194.2013.804521).

Lossos, I.S. and Morgensztern, D. (2006) 'Prognostic biomarkers in diffuse large B-cell lymphoma', *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 24(6), pp. 995–1007. doi:[10.1200/JCO.2005.02.4786](https://doi.org/10.1200/JCO.2005.02.4786).

Matsumoto, K. *et al.* (2018) 'Anemia Associated with Worse Outcome in Diffuse Large B-Cell Lymphoma Patients: A Single-Center Retrospective Study', *Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology*, 35(3), pp. 181–184. doi:[10.4274/tjh.2017.0437](https://doi.org/10.4274/tjh.2017.0437).

Mihara, M. *et al.* (2012) 'IL-6/IL-6 receptor system and its role in physiological and pathological conditions', *Clinical Science (London, England: 1979)*, 122(4), pp. 143–159. doi:[10.1042/CS20110340](https://doi.org/10.1042/CS20110340).

Moore, K.W. *et al.* (2001) 'Interleukin-10 and the interleukin-10 receptor', *Annual Review of Immunology*, 19, pp. 683–765. doi:[10.1146/annurev.immunol.19.1.683](https://doi.org/10.1146/annurev.immunol.19.1.683).

Morais-Perdigão, A. L., Rodrigues-Fernandes, C. I., Araújo, G. R., Soares, C. D., de Andrade, B., Martins, M. D., Vargas, P. A., Pontes, H., Pires, F. R., Burbano, R., & Fonseca, F. P. (2021). CD30 Expression in Oral and Oropharyngeal Diffuse Large B Cell Lymphoma, not Otherwise Specified. Head and neck pathology, 10.1007/s12105-021-01387-5. Advance online publication. <https://doi.org/10.1007/s12105-021-01387-5>.

Nair, R., Kakroo, A., Bapa, A., Gogja., A., & Korula, A., *et al.* (2018). Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group. *Indian J Hematol Blood Transfus*.

Nayak, P.B. *et al.* (2013) 'Centroblastic variant of diffuse large B-cell lymphoma: Case report and review of literature', *Journal of Oral and Maxillofacial Pathology*, 17(2), p. 261. doi:[10.4103/0973-029X.119749](https://doi.org/10.4103/0973-029X.119749).

Ozdemir, F. *et al.* (2004) 'The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive Non-Hodgkin's Lymphoma (NHL)', *Journal of experimental & clinical cancer research: CR*, 23(3), pp. 485–488.

Reksodiputro, H., Irawan, C. and Hardjolukito, E. (2011) 'Non-Hodgkins Lymphoma in Jakarta', *Indonesian Journal of Cancer*, 5(3), p. 69925.

Rungsipipat, A. *et al.* (2014) 'Histopathological classification and immunophenotyping of spontaneous canine lymphoma in Bangkok metropolitan', *Comparative Clinical Pathology*, 1(23), pp. 213–222. doi:[10.1007/s00580-012-1600-9](https://doi.org/10.1007/s00580-012-1600-9).

Schafer, Z.T. and Brugge, J.S. (2007) 'IL-6 involvement in epithelial cancers', *The Journal of Clinical Investigation*, 117(12), pp. 3660–3663. doi:[10.1172/JCI34237](https://doi.org/10.1172/JCI34237).

Sok, M. *et al.* (2019) 'Objective assessment of WHO/ECOG performance status', *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, 27(10), pp. 3793–3798. doi:[10.1007/s00520-018-4597-z](https://doi.org/10.1007/s00520-018-4597-z).



Soria, J.-C. *et al.* (2003) 'Lack of interleukin-10 expression could predict poor outcome in patients with stage I non-small cell lung cancer', *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research*, 9(5), pp. 1785–1791.

Sukpanichnant, S. (2004) 'Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification', *Human Pathology*, 35(2), pp. 224–230. doi:[10.1016/j.humpath.2003.10.007](https://doi.org/10.1016/j.humpath.2003.10.007).

Tanaka, T. and Kishimoto, T. (2012) 'Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases', *International Journal of Biological Sciences*, 8(9), pp. 1227–1236. doi:[10.7150/ijbs.4666](https://doi.org/10.7150/ijbs.4666).

Taylor, C.R. and Hartsock, R.J. (2011) 'Classifications of lymphoma; reflections of time and technology', *Virchows Archiv: An International Journal of Pathology*, 458(6), pp. 637–648. doi:[10.1007/s00428-011-1083-0](https://doi.org/10.1007/s00428-011-1083-0).

Tisi, M.C. *et al.* (2014) 'Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin', *Leukemia & Lymphoma*, 55(2), pp. 270–275. doi:[10.3109/10428194.2013.802314](https://doi.org/10.3109/10428194.2013.802314).

Troppan, K.T. *et al.* (2015) 'The significance of pretreatment anemia in the era of R-IPI and NCCN-IPI prognostic risk assessment tools: a dual-center study in diffuse large B-cell lymphoma patients', *European Journal of Haematology*, 95(6), pp. 538–544. doi:[10.1111/ejh.12529](https://doi.org/10.1111/ejh.12529).

Xiu, B., Lin, Y., Grote, D.M., Ziesmer, S.C., Gustafson, M.P., Maas, M.L., Zhang, Z., Dietz, A.B., Porrata, L.F., Novak, A.J., Liang, A.B., Yang, Z.Z., Ansell, S.M. 2015 ² IL-10 induces the development of immunosuppressive CD14(+) HLA-DR (low/-) monocytes in B-cell non-Hodgkin lymphoma. *Blood Cancer J.* ;5:e328

Yasmeen, T. *et al.* (2019) 'Frequency and causes of anemia in Lymphoma patients', *Pakistan Journal of Medical Sciences*, 35(1), p. 61. doi:[10.12669/pjms.35.1.91](https://doi.org/10.12669/pjms.35.1.91).

Yu, K.-D. *et al.* (2012) 'The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk', *Breast Cancer Research and Treatment*, 131(1), pp. 27–31. doi:[10.1007/s10549-010-1133-3](https://doi.org/10.1007/s10549-010-1133-3).

Zhang, M. *et al.* (2018) 'Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence', *Oncology Letters*, 16(6), pp. 7158–7165. doi:[10.3892/ol.2018.9557](https://doi.org/10.3892/ol.2018.9557)